Skip to content

Identification of psychometric and biological markers to assess androgen and serotonergic sensitivity in relation to sexual functioning in women.

Identification of psychometric and biological markers to assess androgen and serotonergic sensitivity in relation to sexual functioning in women. - Androgen sensitivity in women.

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON34558
Enrollment
200
Registered
2010-12-02
Start date
2010-12-15
Completion date
Unknown
Last updated
2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Female Sexual Dysfunction

Interventions

None listed

Sponsors

Emotional Brain
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. Provision of written informed consent; 2. Female 21-70 years of age; 3. Healthy according to normal results of medical history 4. Subject must be heterosexually oriented; 5. BMI >= 18 and

Exclusion criteria

Exclusion criteria: 1. Subjects who have had hand surgery interfering with measurement of digit lengths; 2. Subjects with musculoskeletal conditions affecting the measurements of digit lengths; 3. Known conditions associated with abnormal prenatal androgen exposure, namely congenital adrenal hyperplasia and complete androgen insensitivity syndrome; 4. Positive drug test and/or positive alcohol test; 5. Subjects with dyslexia; 6. Subjects who are color-blind; 7. Positive urine pregnancy test; 8. Use of oral contraception containing anti-androgens (e.g. Diane 35; Minerva); 9. Use of oral contraception containing 50 µg estrogen or more; 10. Homosexual orientation.

Design outcomes

Primary

MeasureTime frame
1. [CAG]n 2. Calculated second to fourth digit ratio 3. Pre-attentional bias for erotic stimuli (Stroop task) 4. Blood serum free testosterone levels

Secondary

MeasureTime frame
1. Blood serum levels ADT-G, 3a-diol-G, DHEA and DHEA(s) 2. Genotype SERT and 5HT1a receptor 3. Questionnaires: SAQ, SSEQ and SMQ

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)